In commercial swine production, the medicated feed premix is the most direct route for Jianji Powder Veterinary Grade API when oral ingestion over a fixed 7–14-day course is required. The API is blended with a calcium carbonate carrier having a particle size distribution not exceeding 150 µm at a nominal inclusion of 1.0–2.5 wt% in the intermediate premix, corresponding to 200–500 g per metric tonne of complete feed after dilution at the feed mill. The dry-blending operation runs in a single-shaft ribbon mixer with working volume held at 60–70% of rated capacity for 12–18 minutes at 20–25 rpm; batch records from production-scale mixers of 500–1,000 L indicate that loading the API between two thirds of the carrier volume and the remaining carrier reduces dead-zone residue and keeps the coefficient of variation below 5% as measured by ISO 6497:2020 sampling of ferrous tracer. Moisture in the incoming API above 8% is the primary cause of bridging at the rotary screw feeder; pre-drying in a forced-air oven at 40–45 °C for 2–3 hours is required at relative humidity greater than 60%. The homogenized blend is packed as 5% or 10% medicated premix into 25 kg polyethylene-lined paper sacks compliant with Commission Regulation (EU) 2019/4 Annex II for composition and cross-contamination control, with residue carryover limits referenced in Regulation (EC) No 183/2005 for feed hygiene. Because the API contains hygroscopic polysaccharide fractions, the sacked premix should not be stored directly on concrete floors longer than 72 hours; pallet retention of the sealed sack with desiccant sachets maintains a moisture content of 3.5–4.5% and avoids caking.

Injectable formulation: why pH 5.5–6.8 is non-negotiable

When a parenteral route is selected for large animals, Jianji Powder Veterinary Grade API is dissolved in Water for Injection at a concentration of 2.0–4.0 wt% of total extract solids, with 0.9% w/v benzyl alcohol added for multi-dose vials. The pH must be held within 5.5–6.8; above pH 7.0 the tannin–protein complexes precipitate as visible floc and block the 0.22 µm membrane filter during aseptic filling. A 5-micron pre-filter followed by dual 0.22 µm PVDF filters in series is standard practice. Viscosity at 25 °C should remain below 10 mPa·s before filtration; if exceeding this threshold, dilution by an additional 0.3–0.5 volume of WFI is performed rather than increasing pump pressure. Terminal autoclaving at 121 °C for 15 minutes may darken the solution and reduce pH, so sterile filtration followed by aseptic filling is preferred. The filled solution is sealed in 20 mL amber ampoules for single-dose use or 50 mL multi-dose vials with halogenated rubber stoppers. Sterility conforms to Ph. Eur. 2.6.1 and endotoxin is controlled to less than 0.2 EU/mg by Ph. Eur. 2.9.22; particulate matter is validated by Ph. Eur. 2.9.19 for visible and sub-visible particles. Process data from isolator-based filling lines show that the critical hold time between bulk solution preparation and completion of filling should not exceed 8 hours at 10–15 °C to limit microbial bioburden and oxidative degradation of polyphenol fractions. Multi-dose vials require preservative efficacy testing per Ph. Eur. 5.1.3.

Before an in-line medicator delivers a course of treatment to broilers, the water-soluble powder must remain completely dispersible at 5–10 °C, because the drinking water temperature in winter sheds falls into that range. The finished oral powder is prepared by wet granulation in a high-shear mixer with 3–5% w/w of a maltodextrin binder solution, then dried in a fluid-bed dryer at inlet air 60±5 °C, exhaust 38–42 °C, to final moisture ≤4.0%; the dried granules are passed through a 100–212 µm sieve. The API inclusion in the finished water-soluble powder is 15–30 wt%, resulting in an administration rate of 0.25–0.75 g API equivalent per litre of drinking water when a stock solution at 1:50 dilution is metered by a proportional injector. Dispersion time at 10 °C in 150 ppm hardness water is checked against a 30-minute half-life of the suspended matter; if undissolved particles settle faster than that, the batch is reprocessed with an additional 1.0% sodium bicarbonate as a wetting and pH-stabilizing carrier. Compliance for the dosage form sits under EU GMP Part II for veterinary oral soluble powders and the general monograph for granules and powders for oral solutions referenced in Ph. Eur. 2.9.12 for particle size distribution. The terminal packaging is 100 g and 500 g laminated foil sachets with a desiccant window, and the labelled content is verified by HPLC for marker polysaccharide hydrolysate rather than by UV absorbance alone.

Compression of high-fiber extract powders on rotary tablet presses

Direct compaction of the powder into tablet form requires substitution of the API’s natural high hygroscopicity with a microcrystalline cellulose-based direct compression matrix. Each 500 mg scored tablet contains 120–200 mg of API, corresponding to 24–40 wt% of tablet mass; the remaining mass is formed by microcrystalline cellulose at a 50/50 blend of PH-101 and PH-102, 3.0 wt% croscarmellose sodium, 1.5 wt% colloidal silicon dioxide, and 1.0 wt% magnesium stearate. The blend is mixed in a 200 L V-blender for 15 minutes at 15 rpm, with the lubricant added in the final 3 minutes to avoid shear-induced hydrophobic film formation. Compression is carried out on a 16-station rotary tablet press at 20–25 kN, dwell time 20–35 ms, and turret speed 60–80 rpm; pre-compression force is set at 4–6 kN to release air from the high-fiber material. Tablets must remain below 0.8% friability by USP 1216 and disintegrate within 30 minutes in 900 mL water at 37±2 °C per USP 701. At relative humidity above 50%, the powder picks up moisture rapidly and causes picking on the upper punch; feeding room RH must be maintained at 35–45% and the granulation bowl is used only for a 30-minute homogenization of the dry blend if the sieve fraction below 74 µm exceeds 60%. Terminal product is a 30-, 60-, or 90-count HDPE bottle with a desiccant canister and induction-sealed liner, labelled for companion-animal oral administration.

For transition dairy cows, the need for a rapidly absorbed oral solution differs sharply from a dry top-dress because first-pass rumen degradation can reduce the availability of the ethanol-soluble fractions if they are exposed to rumen microflora for more than 2 hours. An oral drench is prepared by dispersing the API at 5.0–8.0 wt% in a propylene glycol and purified water base with 0.2% w/v sodium benzoate and citric acid to pH 5.5–6.0. The mixing vessel is a high-shear overhead mixer operated at 1,500–2,000 rpm for 25–30 minutes; if the batch temperature exceeds 45 °C, the polysaccharide fraction gels and the in-line 100 µm strainer becomes fouled, so a jacketed vessel with 15 °C chilled water is used. After mixing, the liquid is passed through a 100 µm strainer and filled at 100–250 mL into 500 mL HDPE bottles or 100 mL single-use drench vials. The liquid dosage form is tested for microbial enumeration via Ph. Eur. 2.6.13, with a specification of total aerobic microbial count not exceeding 10³ CFU/g and total combined yeast and mold count not exceeding 10² CFU/g; absence of Escherichia coli per Ph. Eur. 2.6.13 is mandatory because the oral drench is often administered to periparturient cows in a barn environment. Impurity profiling follows VICH GL18 for potential degradation products arising from the extraction process; if the API is derived from an ethanol extract, residual ethanol in the finished drench must not exceed 0.5% v/v and is controlled by gas chromatography with headspace injection. Batch retention time at 20–25 °C should be limited to 48 hours before filling because the non-preserved aqueous phase supports fermentative darkening at a pH above 6.5.

Equine feed top-dress granules require a different drying endpoint

Wet granulation of the API for equine feed top-dress produces a free-flowing granule with a tendency to clump if the drying endpoint is set by residual moisture alone. The API is included at 15–25 wt% of the finished granule blend, and the daily dose is 10–20 g per 500 kg body weight. The granulation liquid is a 30% ethanol-water solution added at 8–12% w/w of the dry powder mass in a high-shear granulator; impeller speed is held at 1,200–1,500 rpm for 3–5 minutes, followed by a 1.5 mm conical mill wet sizing. Fluid-bed drying uses inlet air 35–40 °C for 45–60 minutes, with final moisture of 3.0–4.2%; a forced-air oven at 50 °C should be avoided because the outer crust forms a diffusion barrier that leaves core moisture above 6% and causes mold growth in the bulk pack. The dried granules are passed through a 500 µm to 1.18 mm oscillating screener, and fines below 180 µm are recycled only if they constitute less than 10% of the batch. Compliance for equine oral granules is anchored to the European Pharmacopoeia general monograph for granules and to the FEI Clean Sport Prohibited Substances List if the product is intended for competition horses; every batch must be screened for boldenone-like plant sterols and for the presence of undeclared alkaloid markers using LC-MS/MS. The terminal pack is a 2.5 kg bucket or 10 kg bag with a calibrated 20 g scoop, sealed with a foil membrane and stored at or below 25 °C.